Today: 19 May 2026
Macquarie share price ends higher after $685 million IHS tower deal — what MQG investors watch next
18 February 2026
1 min read

Macquarie share price ends higher after $685 million IHS tower deal — what MQG investors watch next

Sydney, Feb 18, 2026, 17:12 AEDT — Market closed

  • Macquarie finished 0.6% higher, settling at A$219.60.
  • The asset management division has struck a deal to acquire IHS Towers’ tower assets in South America, with the transaction slated to wrap up sometime later in 2026.
  • Macquarie’s full-year earnings, set for release May 8, mark the next big catalyst.

Macquarie Group Ltd finished up 0.57% at A$219.60 on Wednesday, following news that its asset management unit plans to acquire IHS Towers’ South American wireless tower assets. The deal values the business, including debt, at $685 million.

The market is closed, sure, but timing is what matters here. Macquarie continues allocating capital into private infrastructure, a space investors track closely—those assets generate management fees that aren’t tied to day-to-day market moves.

Wireless towers don’t get much of the telecom spotlight. Operators lease them, the towers generate steady rental income, and their business rhythm typically diverges from the tempo of stock trades or deal-making.

Macquarie Asset Management is picking up the assets for a privately managed infrastructure fund, assigning an implied enterprise value of roughly R$3,550 million (US$685 million) under U.S. GAAP, not counting cash or IFRS 16 lease liabilities. “We expect further wireless and digital infrastructure investment will be required to support 5G network buildout in Brazil and Colombia over the next several years,” said Fernando Lohmann, who leads the firm in Brazil. Macquarie

IHS Towers is selling its Latin American tower business, assigning the deal an enterprise value of roughly $952 million with lease liabilities factored in. The portfolio covers around 8,860 sites. “We are today announcing the sale of our Latam tower operations to Macquarie Asset Management, marking our exit from the Latam region,” Chairman and CEO Sam Darwish said. IHS Towers Corporate

Macquarie moved higher as the broader market caught a bid. Australia’s S&P/ASX 200 finished roughly 0.5% stronger, regional stocks also in the green—though some investors were still chewing on renewed concerns about how fast, and how much, the AI boom might deliver.

Still, this one’s not locked in. The acquisition, slated to wrap up sometime later in 2026, faces a list of conditions to clear. And there’s the risk: if funding costs climb or currency shifts eat into returns, tower economics could quickly turn complicated.

Then there’s the seller’s side. MTN Group announced plans to acquire full ownership of IHS Holding, putting an estimated $6.2 billion price tag on the tower company. Once that’s done, IHS is headed for the private markets, Reuters reported.

MQG holders are staring at the details now: how the tower platform’s paid for, what Macquarie can actually pull off in a yield-hungry but cautious market, and if a string of new infrastructure deals shows up fast.

Next up: Macquarie’s full-year results drop Friday, May 8. Shares go ex-dividend the following Monday, May 18—so anyone buying on or after that day misses the payout. The record date falls just after, on May 19.

Stock Market Today

  • Aurionpro Solutions Earnings Reveal Cash Flow Concerns Despite Profit
    May 18, 2026, 9:32 PM EDT. Aurionpro Solutions (NSE:AURIONPRO) reported a profit of ₹2.13 billion for the year ending March 2026, but free cash flow (FCF) showed a deficit of ₹1.1 billion, indicating poor cash conversion. The accrual ratio, which measures profit quality, stood at 0.24, signaling profits not backed by cash flow-a potential red flag suggesting statutory profits may overstate underlying earnings power. Positive cash flow of ₹619 million recorded a year earlier shows the company can generate cash, yet recent performance raises concerns. Despite this, earnings per share (EPS) growth over three years remains strong. Investors should note two identified risks, emphasizing the need for cautious analysis beyond headline figures.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Strike threat at Futamura: Wigton packaging workers reject 1.2% pay rise, set vote
Previous Story

Strike threat at Futamura: Wigton packaging workers reject 1.2% pay rise, set vote

British American Tobacco share price rises early as BAT reiterates 2026 outlook and keeps buyback running
Next Story

British American Tobacco share price rises early as BAT reiterates 2026 outlook and keeps buyback running

Go toTop